Genome-wide Studies of Copy Number Variation and Exome Sequencing Identify Rare Variants in BAG3 as a Cause of Dilated Cardiomyopathy  by Norton, Nadine et al.
ARTICLE
Genome-wide Studies of Copy Number Variation
and Exome Sequencing Identify Rare Variants
in BAG3 as a Cause of Dilated Cardiomyopathy
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Dilated cardiomyopathy commonly causes heart failure and is the most frequent precipitating cause of heart transplantation. Familial
dilated cardiomyopathy has been shown to be caused by rare variantmutations inmore than 30 genes but only ~35% of its genetic cause
has been identified, principally by using linkage-based or candidate gene discovery approaches. In a multigenerational family with auto-
somal dominant transmission, we employed whole-exome sequencing in a proband and three of his affected family members, and
genome-wide copy number variation in the proband and his affected father and unaffected mother. Exome sequencing identified
428 single point variants resulting in missense, nonsense, or splice site changes. Genome-wide copy number analysis identified 51
insertion deletions and 440 copy number variants > 1 kb. Of these, a 8733 bp deletion, encompassing exon 4 of the heat shock protein
cochaperone BCL2-associated athanogene 3 (BAG3), was found in seven affected family members and was absent in 355 controls. To
establish the relevance of variants in this protein class in genetic DCM, we sequenced the coding exons in BAG3 in 311 other unrelated
DCM probands and identified one frameshift, two nonsense, and four missense rare variants absent in 355 control DNAs, four of which
were familial and segregated with disease. Knockdown of bag3 in a zebrafish model recapitulated DCM and heart failure. We conclude
that new comprehensive genomic approaches have identified rare variants in BAG3 as causative of DCM.Introduction
Dilated cardiomyopathy, (DCM [MIM115200]), a common
primary myocardial disease, causes systolic dysfunction
and heart failure, a major public health problem. Familial
dilated cardiomyopathy has been shown to be caused by
rare variant mutations in more than 30 genes, most of
which encode sarcomeric or sarcomeric-associated
proteins.1,2 However, mutations in the known genes only
account for ~35% of genetic causes, leaving the majority
of them unknown. This highlights two observations: (1)
additional rare variants in other genes remain to be found
and (2) rare copy number variants (large deletions and
duplications > 1 kb) have been largely ignored in DCM
genetics. These types of genetic variation would be missed
by traditional sequencing approaches to coding regions
because of the background presence of the wild-type allele.
At this time, no systematic study of the contribution of
copy number variation to DCM has been performed.
On these bases, we simultaneously performed exome
sequencing and a high-resolution genome-wide study of
copy number variation on a large multiplex family
(Figure 1) with DCM. The family was previously screened
for coding mutations in 15 known DCM genes and was
mutation negative.3–7 Exome sequencing was performed
with NimbleGen solution-based capture and Illumina
76 bp read next-generation sequencing. Copy number
variation was assessed with NimbleGen 2.1M catalog1Cardiovascular Division, Department of Medicine, University of Miami Miller
Sciences, University of Washington, Seattle, WA 98195-5065, USA; 3Hussm
Medicine, Miami, FL 33136-1015, USA; 4Division of Nephrology, Departmen
33136-1015, USA
*Correspondence: rhershberger@med.miami.edu
DOI 10.1016/j.ajhg.2011.01.016. 2011 by The American Society of Human
The Ameriarrays, followed by NimbleGen 135K custom arrays, allow-
ing detection of deletions and duplications at the resolu-
tion of a single exon. Our approach identified a deletion
of exon 4 of BCL2-associated athanogene 3 (BAG3) (MIM
603883) as a rare variant causative of DCM. Furthermore,
post hoc analyses of our genomic data suggest that both
point mutations and rare copy number variants can be
identified from a single genomic platform (Figures S3A
and S3B, available online), further development of which
will have a significant impact on the discovery of
unknown genetic causes of cardiovascular disease.
Material and Methods
Subjects
Written, informed consent was obtained from all subjects, and the
institutional review boards at the Oregon Health and Science
University and the University of Miami approved the study. The
investigation included 311 probands with DCM as previously
described.5,6,8 The investigation also included a total of 355 popu-
lation controls: 45% male, 97% white, and 3.0% African Amer-
ican. Genomic DNA was extracted from whole blood according
to a standard salting-out procedure. Prior to the current study,
we sequenced the coding and flanking intronic regions of 15
DCM genes in genomic DNA from these probands.3–7
Exome Sequencing
Three to five micrograms of DNA from four family members
affected with DCM (pedigree A, Figure 1) were sent to theSchool of Medicine, Miami, FL 33136-1015, USA; 2Department of Genome
an Institute for Human Genomics, University of Miami Miller School of
t of Medicine, University of Miami Miller School of Medicine, Miami, FL
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Figure 1. Pedigrees of BAG3-Associated Dilated Cardiomyopathy
Pedigrees have been labeled by letter, which correspond to their respective mutation as shown in Table 3. Squares represent males and
circles represent females. An arrowhead denotes the proband. A diagonal line marks deceased individuals. Solid symbols denote dilated
cardiomyopathy with other causes except genetic ruled out. Open symbols denoteunaffected individuals. The presence or absence of the
pedigree’s BAG3mutation is indicated by a þ or  symbol, respectively; obligate carriers are noted in parenthesis, (þ). Individuals who
underwent exome sequencing are denoted (exome), as are those who underwent comparative genomic hybridization (CGH).University of Washington Genome Sciences for exome capture
and sequencing. These samples were sent as a batch, (a total of
20 samples across five DCM families). The remaining exome
data are under investigation and will be published elsewhere.
Sequence capture was performed in solution with a NimbleGen
probe library that included a 26.4 Mb target sequence (152,917
exons from 16,515 genes). Exome sequencing was performed on
the Illumina GAIIx platform with paired-end 76 base reads.
Fastq sequence files were aligned against the human reference
sequence (hg18) with the Burrows-Wheeler Aligner (BWA).9
Duplicate paired-end reads were removed from the merged data
sets. SNP and indel calling was performed with the GATK Unified
Genotyper and annotated with SeattleSeq SNP annotation. To
insure sample identity at each stage in the process, we genotyped
all samples (Illumina BeadXpress) prior to exome sequencing for
96 high-allele-frequency, exome-specific polymorphisms and
compared them to polymorphisms derived from both lane and
merged exome data. Variants with either quality scores % 50,
allelic imbalance R 0.75 (number reads a reference allele as a
proportion of total number of reads), homopolymer runs > 3 of
the variant allele, or read depth < 5 were filtered out. We further
filtered out those variants with a heterozygous genotype in
20 out of 20 exomes from five DCM families (all sequenced in
the same batch at the University of Washington) assuming these
to be false positives.
We assumed an autosomal dominant model and prioritized
nonsynonymous, splice site, and insertion/deletion variants that
were heterozygous and shared across all four affected individuals;
not present in dbSNP (build 131), 1000 Genomes Project, and also
not present in a further eight exome sequences from HapMap
individuals;10 and also not present in eight exome sequences
from a pedigree with spastic paraplegia.11 The remaining variants
were further prioritized by transcriptome data generated in our
laboratory from left ventricular myocardium of two control
samples and two unrelated DCM samples.We determined variants
with reads per kilobase of exon model per million mapped reads
(RPKM) > 3 in any of the four transcriptome data sets as being274 The American Journal of Human Genetics 88, 273–282, March 1expressed in left ventricular myocardium. Of the remaining vari-
ants, we further prioritized those that were unique to pedigree A.
Remaining variants that were also present in the exome sequences
of four additional DCM families (16 additional exome sequences
sequenced in the same batch at the University of Washington),
and that did not segregate with disease in these families, were
assumed to be polymorphisms.Comparative Genomic Hybridization
Three micrograms of DNA from the proband of pedigree A were
sent to NimbleGen to perform comparative genomic hybridiza-
tion (CGH) on the NimbleGen 2.1M HD2 catalog microarray,
median probe spacing 1.2 kb. Microarrays were scanned with
the NimbleGen MS200 scanner at 2 m resolution. We used three
different algorithms to score copy number variants (CNVs):
NimbleGen segMNT, Nexus copy number (BioDiscovery), and
wuHMM.12 Copy number variants were viewed in the Nexus
Copy Number software (version 4.1) and scored with a log2
ratio 50.2. CNV regions called with any one of the three algo-
rithms with less than 50% overlap with variants in the database
of genomic variants13 were designed onto a custom NimbleGen
135K array with average probe spacing of ~156 bp, including
3 kb flanking sequence and backbone probe spacing every
~100 kb across each autosome. Validation of putative CNV’s not
present in the database of genomic variants was performed with
custom array CGH on the proband and also in both parental
DNA samples at the Florida State University core microarray
facility following standard NimbleGen protocols. We prioritized
the validated CNV’s as those inherited from the affected parent
and overlapping exons as putative disease causing.Transcriptome Sequencing
RNAwas extracted from frozen left ventricular myocardium of two
normal and two DCM hearts with Trizol reagent and purified with
QIAGEN RNeasy columns and treated with 20 U DNase with
RNase inhibitor. RNA yield and purity was assessed with the1, 2011
RNA 6000 Nano Kit RNA and Agilent 2100 Bioanalyzer. RNAs with
integrity number (RIN)> 7.8 were used for cDNA synthesis. Poly-A
containing mRNA was isolated by poly-T oligo-attached magnetic
beads. cDNA libraries were prepared with Illumina’s mRNA-Seq
Sample Prep kit according to the manufacturer’s instructions.
Briefly, mRNA was fragmented into small pieces (~200 bp) with
divalent cations in the fragmentation buffer at 94C for 5 min.
Cleaved RNA fragments were transcribed into first-strand cDNA
with SuperScript II (Invitrogen) reverse transcriptase and random
primers. This was followed by second-strand cDNA synthesis
with DNA Polymerase I and RNase H. The designated adaptor oli-
gos were ligated to the ends of the DNA fragments with T4 DNA
ligase. Gel isolation was used to extract expected cDNA fragments.
Limited PCR amplification (15 cycles) with two primers annealed
to the ends of the adaptors was performed to enrich the purified
cDNA templates. Paired-end sequencing was performed at the
University of Miami Hussman Institute of Human Genomics on
the GAII Illumina platform with mRNA-Seq Cluster Generation
kits (76 cycles). Data collection, base calling, and preliminary
data analysis were performed with standard Illumina software.
Sequence alignment to human reference sequences and expres-
sion quantification in RPKM were performed with the NextGENe
software package (SoftGenetics, State College, PA). RPKM is the
number of reads that map per kb of exon model per million map-
ped reads for each gene.14 We used a RPKM > 3 as criteria for
expression in the heart. Despite this low threshold, it is possible
that some cardiac genes would not be identified by this criteria
because of the small number of samples in the data set (n ¼ 4).
Long-Range PCR across BAG3, ATE1,
and DOCK1 Deletions
PCR assays were used to genotype putative disease causing dele-
tions in the remaining family members to assess segregation
with disease. We used the Phusion PCR amplification kit (Finn-
zymes, New England Biolabs) under the manufacturer’s instruc-
tions at annealing temperatures of 68C for BAG3 and DOCK1
(MIM 601403) and 70C for ATE1 (MIM 607103). Assays were de-
signed with forward and reverse primers set outside of the deleted
regions and an additional forward primer inside of the deletion
breakpoint to simultaneously amplify the wild-type fragment.
Primer sequences are shown Table S1.
Sanger Sequencing of BAG3 Coding Region in 311
Probands and 180 Population Controls
Bidirectional Sanger sequencing of the BAG3 coding region
(NM_004281.3), in 311 DCM probands was run on a 3130xl as
previously published.3–7 We were unable to consistently amplify
exon 1. Primer sequences are shown in Table S1. Exons 2, 3, and
4 were also sequenced in 180 population controls.
Screening for Missense, Nonsense, and Frameshift
Mutations in an Additional 175 Population Controls
DNA pools of n ¼ 7 or n ¼ 8 population controls (14–16 chromo-
somes) were constructed. We used SNaPshot primer extension
(Applied Biosystems) to test for the presence of BAG3 missense,
nonsense, and frameshift mutations in population controls from
22 DNA pools. Primer extension reactions were run on a 3130xl
DNA sequencer (Applied Biosystems). Prior to pool construction,
each DNA sample was placed on a rotator in a cold room for one
week to ensure DNA homogeneity, then PCR amplified by long-
range PCR to test for sample quality and amplification. Subdilu-The Ameritions of approximately 30 ng/ml were made for each sample based
on the initial reading by spectrophotometer. Each subdilution was
then quantified four times by nanodrop. All samples were quanti-
fied on the same day. On the basis of the average reading, a total of
600 ng of each DNA sample was pooled. The final DNA pools were
diluted to a concentration of 20 ng/ml. Validation of the DNA
pools is described in Supplemental Data.Zebrafish Bag3 Knockdown
Zebrafish Lines
Wild-type Tu¨AB zebrafish were maintained and raised as described
previously.15 Dechorionated embryos were kept at 28.5C in E3
solution with or without 0.003% 1-phenyl-2-thiourea (PTU;
Sigma) to suppress pigmentation and were staged according to
somite number (som) or hours postfertilization (hpf).15
Morpholino Antisense Oligonucleotide Injections
To study the effects of altered expression of bag3 in zebrafish, two
morpholino oligonucleotides directed against the translation start
codon (50-CAGAGGATCGTTAGTTGCCATCGTT) and splice donor
sites of exon 2 (50-GCTTTCTCATGATCTTACCTCAGGC) were
purchased from Gene Tools (Philomath, OR) and injected into
one- to two-cell-stage zebrafish embryos as previously described.16
The cardiac morphology and function as well as the general devel-
opment of fish were evaluated at 24, 48, and 72 hpf.
PCR primers were designed in flanking exon sequences to eval-
uate the efficacy of the bag3 exon2 splice-blocking morpholino
oligonucleotide and to characterize mRNA splicing products in
cDNA isolated from both wild-type and morphant embryos. The
following nested PCR primer sets were designed to amplify both
wild-type and morphant mRNA fragments: outF-50-ATCAAAATT
GACCCGCAGAC-30, outR-50-CCCGGAGACCTGTATTGCT-30 and
inF-50-ATCACAACAATCGCACAACG-30, inR-50-GGTGAAGGCCA
CTGATTTGT-30. RT-PCR analysis of wild-type embryos produced
an amplification product of 408 bp, whereas two products of
408 and 99 bp were generated from the bag3 exon2 morpholino-
treated embyros showing the alternate splicing of exon 2
(Figure S2). These RT-PCR amplicons were gel extracted and
sequenced with standard Sanger sequencing protocols. The
408 bp fragment from bothwild-type andmorphant embyros con-
tained exon 2 sequence, whereas the 99 bp fragment contained
sequence from only exon 1 and exon 3. The resulting deletion
of exon 2 yielded an in-frame sequence for the remainder of the
protein.
Zebrafish Image Analysis and Cardiac Measures
Approximately 1200 frames were recorded for each ventricular
measurement of fractional shortening (FS) and peak flow velocity.
FS movies were recorded at 120 frames per s and peak flow
velocities were recorded at 240 frames per s with a Grasshopper
high-speed video camera (Point Grey Research, Vancouver). All
measurements were performed with ImageJ software. FS was deter-
mined as the ventricle area (in pixels) at diastole minus the area at
systole as a proportion of the area at diastole 3 100. FS was calcu-
lated for three heart cycles in each fish. Peak flow measurements
were taken by mapping the coordinates of a single blood cell in
ImageJ every eight frames (equivalent to every 0.033 s). A correc-
tion factor to convert pixels to distance was determined as per
Shin et al.,17 allowing the velocity to be calculated as distance
divided by time. We measured the velocity of three blood cells
(each in a different heart cycle) per fish in a total of six wild-type
and six ATG morphant embryos. Significance was determined by
an unpaired t test with unequal variance.can Journal of Human Genetics 88, 273–282, March 11, 2011 275
Table 1. Heterozygous Variants Identified by Exome Sequencing
and Shared between Four Affected Individuals in pedigree A
Pedigree A: Exome Variants (Single Base and Small Insertion
Deletions)
Missense, nonsense, splice, indel 479
Not present in dbSNP build 131
or 1000 Genomes Project
13
Expressed in heart TTLL5, TUBGCP6, FRG1, C1orf163
Unique to DCM pedigree A TTLL5Results
Exome-Sequencing Quality Control
Exome data were generated on the Illumina GAIIx with
paired-end 76 base reads and multilane data merged. We
generated an average of 75 M total reads, with 55 M
mapping to the exome target for analysis. All duplicate
read pairs were removed. All samples had a 104-fold
average coverage [range 52–172] and an average of 86%
of the exome target region at >20-fold coverage. Concor-
dance with presequencing fingerprint variant set was
>99% across all samples. On average 16,407 variants posi-
tions were identified across these samples.
We previously sequenced our DCM cohort in 15 known
DCMgeneswithbidirectional Sanger sequencing.3–7Exome
datawere generated forfiveunrelated individuals (including
the proband from pedigree A) with Sanger sequencing
data available, and of the 15 genes screened by Sanger
sequencing, 11 were also present on the exome capture
design andwithin these genes. Notably, 35 out of 35 hetero-
zygous coding variants identified by Sanger sequencing in
these 11 genes were also identified in the exome-sequence
data, suggesting both an extremely low false negative rate
and high genotyping accuracy by the GATK software.
Exome Sequencing Did Not Identify Genetic Cause
in a Multiplex DCM Family
The number of shared variants observed with exome
sequencing in four affected pedigree A individuals areTable 2. Iterative Approach Identifying CNV with Comparative Genom
Pedigree A: CNV Variants No. CNVs Loss Mea
Total (2.1M array) 440 180 48,0
<50% overlap with DGV 81 21 14,4
Designed onto 135K custom array 41 7 23,8
Validated by custom array 9 6 24,0
Inherited from affected father 6 5 27,5
Spanning exons 5 4 32,1
Expressed in heart BAG3, ATE1, DOCK1 3 30,3
Segregation with DCM BAG3 1 8,73
DGV is an abbreviation for database of genomic variants and NA is an abbreviatio
a CNV sizes are given in base pairs.
276 The American Journal of Human Genetics 88, 273–282, March 1shown at each filtering stage (Table 1). At the final filtering
stage, a single missense variant (c.626G>A [p.Arg209His]),
position chr14: 75,243,154 (hg18) in tubulin tyrosine ligase-
like family, member 5, (TTLL5, NM_015072.4), (MIM
612268) remained. Genotyping in the extended family
showed that it was absent from 1 of the 7 affectedmembers
and was also present in 4 of 12 unaffected family members,
suggesting it was unlikely to be relevant for DCM.
In addition to TTLL5, a second variant passing all
filtering criteria with the exception that it was not unique
to pedigree A was found in the gene TUBGCP6, (MIM
610053). This missense variant was also present in one of
two affected exome data sets from a second DCM family.
We screened additional DNA samples in pedigree A for
the TUBGCP6 variant and found this to be nonsegregating.
The variant was also present in 3 out of 88 population
controls and was thus considered a polymorphism. Two
missense variants in the genes FRG1 (MIM 601278) and
C1orf163, expressed in the heart, were present in all four
exome sequences from pedigree A. These variants were
present in a total of 19 out of 20 of our affected DCM
exome data sets and were not further considered.
High-Density Genome-wide Assessment
of Copy Number Variation
Genome-wide copy number analysis with NimbleGen
2.1M CGH arrays on the proband in pedigree A is summa-
rized in Table 2. A total of three CNVs were inherited from
the affected father and spanned exons and genes expressed
in heart: BAG3 (8.7 kb), ATE1 (15.6 kb), and DOCK1 (67.1
kb). Deletions in BAG3 and ATE1 spanned the last exon of
each gene with breakpoints in the final intron and 30 flank-
ing regions. We designed PCR assays across the BAG3,
ATE1, and DOCK1 deleted regions, including a third
primer inside of the deletion, and we genotyped all avail-
able DNA samples in pedigree A. All seven of the affected
members were heterozygous for the BAG3 deletion
(Figure 1), which was not present in 355 population
control DNA specimens. The ATE1 deletion was also
heterozygous but was absent from two of seven affectedic Hybridization in Pedigree A
n Sizea Median Sizea Gain Mean Sizea Median Sizea
74 13,573 260 62,662 12,868
33 5,699 60 12,864 9958
41 13,223 34 16,395 9252
17 11,930 3 10,835 8264
17 15,004 1 8264 8264
82 26,511 1 8264 8264
12 15,615 0 NA NA
3
n for not applicable.
1, 2011
Table 3. Variants Identified by Sequencing BAG3
Exon UCSC hg18 Nucleotide Change Amino Acid Change Phastcon Score GERP Score Ped ID Present in Controls
2 chr10:121419383 c.211C>T p.Arg71Trp 0.067 2.50 B no
2 chr10:121419440 c.268C>T p.Arg90stop 0.996 5.05 C no
2 chr10:121419498 c.326A>G p.His109Arg 0.585 4.23 D no
2 chr10:121419539 c.367C>T p.Arg123stop 0.479 2.36 E no
3 chr10:121421901 c.652 delC p.Arg218GlyfsX89 NA NA G no
3 chr10:121422033 c.784G>A p.Ala262Thr 0 2.56 F no
4 chr10:121426486 c.1430G>A p.Arg477His 1 5.46 H no
2 chr10:121419452 c.280A>T p.Ile94Phe 1 5.05 - yes (2)
2 chr10:121419602 c.430A>G p.Thr144Ala 0.001 1.14 - yes (1)
3 chr10:121421902 c.653G>A p.Arg218Gln 0.168 4.93 - yes (1)
3 chr10:121422141 c.892G>A p.Val298Met 0.001 0.08 - yes (1)
Conservation measured by Phastcons and GERP scores. Nucleotide positions based on reference sequence NM_004281.3. NA is an abbreviation for not
applicable.members. Both deletions map to within 2 Mb of each
other on chromosome 10q26, suggesting recombination
between them. The DOCK1 deletion was present only in
the proband and father.
Identification of BAG3 Point Mutations in Additional
DCM Families
BAG3 is highly expressed in the heart, as shown by both
transcriptome data from our laboratory and the litera-
ture.18 A point mutation in BAG3 is already known to
cause fulminant skeletal myopathy and early lethality in
knockout mice18 and myofibrillar myopathies (MIMThe Ameri612954) with restrictive (RCM [MIM 115210]) or hyper-
trophic (HCM [MIM 192600]) cardiomyopathy in hu-
mans.19,20 To seek further evidence that mutations in
BAG3 cause DCM, we resequenced exons 2, 3, and 4 in
311 additional DCM probands previously resequenced
for 15 other genes.3–7 We identified point mutations in
seven unrelated probands, including two premature stop
codons and one frameshift (Table 3, Figure 2) that were
absent in 355 in-house population controls and over 967
exomes sequenced at Seattle Seq (a total of 2644 chromo-
somes). One stop codon and a frameshift mutation were
identified in sporadic cases, suggesting, as with theFigure 2. Summary of BAG3 Function
Adapted from McCollum et al.22 and
annotated with mutations identified in
DCM families.
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Table 4. Clinical Characteristics
Subject
Age at
Diagnosis or
Screening Gender DCM ECG/Arrhythmia
LVEDD
(mm),
Z Score
Ejection
Fraction
LV Septum/
Posterior
Wall Thickness
(mm)
Mutation
Status
(Yes, No,
Unknown) Comment
Pedigree A: 8.7 kb Deletion
II.4 75 F no 40, NA 60 8/11 no
II.8 64 F yes NSSTT,
Q’s V1-V2
55, 2.91 15 8/14 yes coronary
angiogram negative
III.1 51 M no 39,
3.24
55 9/11 no
III.2 62 M no 54.6,
1.14
63 11/12 no
III.3 60 F no 41.5,
1.21
50 11/8 no
III.4 57 F no sinus bradycardia;
minimal voltage
criteria for LVH
51.2, 1.89 63 11/8 no
III.5 48 M yes RBBB 64, 3.61 30 9/11 yes
III.7 44 M yes Q’s V1–V3, LAE NA 15 NA yes echocardiogram:
LV severely dilated
with global
hypokinesis,
coronary
angiogram
negative; died of
advanced heart
failure at age 44
III.8 54 M yes Q’s III, F 68, 4.34 33 yes no known coronary
disease
III.10 52 M no 50,
0.24
68 no
III.11 39 M no 52, 0.47 60 no
III.12 35 F yes LVH 77, 8.15 17 6/9 yes died of advanced
heart failure at age
38
III.13 58 M no 46,
1.39
58 no
III.14 57 M no 46,
1.42
58 11/13 yes
III.15 54 M yes NSSTT 60, 2.30 48 14/13 yes
III.16 47 M no NSR 39,
3.80
68 no
IV.1 23 M yes Q’s V1-V2,
PVCs, LAD
75, 6.18 7 8/7 yes heart transplant,
age 23; no coronary
disease
IV.2 22 F no 50, 1.32 60 NA yes
IV.3 32 M no LVH 54,1.13 60 11/7 no
IV.4 24 F no low voltage
QRS
50, 1.09 58 9/9 yes
Pedigree B: p.Arg71Trp
I.2 59 F yes Q’s V1-V2, PVCs NA 20 NA yes heart transplant,
age 65; coronary
angiogram negative
II.1 41 M yes iLBBB, AF,
LAD, RVR
71.2, 4.46 24 7/9 yes coronary
angiogram negative
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Table 4. Continued
Subject
Age at
Diagnosis or
Screening Gender DCM ECG/Arrhythmia
LVEDD
(mm),
Z Score
Ejection
Fraction
LV Septum/
Posterior
Wall Thickness
(mm)
Mutation
Status
(Yes, No,
Unknown) Comment
Pedigree C: p.Arg90Stop
I.1 44 M yes Q’s III, F, V1; LAE 70, 4.98 24 8/8 yes no coronary
disease, idiopathic
dilated
cardiomyopathy by
medical records
Pedigree D: p.His109Arg
I.1 21 M yes nonspecific IVCD 79, 6.32 25 7/7 yes no coronary
disease, idiopathic
dilated
cardiomyopathy by
medical records
Pedigree E: p.Arg123Stop
I.1 36 M unknown NA NA NA NA yes heart transplant,
age 40; medical
records unavailable
to categorize
cardiomyopathy
II.1 25 M yes NA 74, 5.14 25 8/8 yes ventricular assist
device, heart
transplant, age 26
II.2 34 F Systolic
dysfunction
NA 49.5, 1.31 48.3 10/9 yes asymptomatic with
mild LV
dysfunction;
coronary
angiogram negative
II.3 31 F Yes NA 49.5, 1.44 37.5 9/9 yes asymptomatic
Pedigree F: p.Ala262Thr
I.1 65 M Yes NA NA NA NA unknown DCM, no coronary
disease by medical
records
II.1 42 M Yes 1AVB,
Q’s V1-V3, LAE
NA (severely
dilated)
15 NA yes ICD, heart
transplant, age 43;
coronary
angiogram negative
II.2 44 M Yes 1AVB,
Q’s V1-V2,
LAFB, LAD
68, NA 28 NA yes heart transplant,
age 45
Pedigree G: p.Arg218GlyFsX89
1.1 47 M Yes NSSTT 60, 2.90 25 NA yes died, age 54;
coronary
angiogram negative
Pedigree H: p.Arg477His
II.3 47 M Yes NSCD,
NSSTT
80, 6.52 15 9/9 yes heart transplant,
age 57; coronary
angiogram negative
III.1 50 M Yes iBBB, LPFB,
NSSTT
76, 5.88 5 NA yes ventricular assist
device, heart
transplant, 50
years; coronary
angiogram negative
The following abbreviations are used: 1AVB, first-degree atrioventricular block; AF, atrial fibrillation; DCM, dilated cardiomyopathy; iBBB, incomplete bundle
branch block; ICD, implantable cardiac defibrillator; iLBBB, incomplete left bundle branch block; IVCD, interventricular conduction delay; LAD, left axis deviation;
LAE, left atrial enlargement; LAFB, left anterior fasicular block; LV, left ventricle; LVEDD, left ventricular end-diastolic dimension; LVH, left ventricular hypertrophy;
LPFB, left posterior fasicular block; MI, myocardial infarction pattern; NA, not available; NSCD, nonspecific conduction delay; NSR, normal sinus rhythm; NSSTT,
nonspecific ST-T changes; PVC, premature ventricular contraction; RBBB, right bundle branch block; RVH, right ventricular hypertrophy; RVR, rapid ventricular
response.
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Figure 3. Morpholino Knockdown of bag3 in Zebrafish Causes Cardiac Phenotypes
Whole-mount brightfield images of 72hpf zebrafish embros. (A) wild-type, (B) bag3ATG morpholino-injected, (C) exon 2 splice donor-
blockingmorpholino-injected embryos. Measurement of cardiac performance comparing wild-type andmorphant embryos for (D) frac-
tional shortening and (E) peak flow velocity averaged across all data points from onset of systole. ATG morpholino injected at 0.5 mM
and exon 2morpholino injected at 0.3 mM. Arrowsmark pericardial effusion. The following abbreviations are used:WT, wild-type; MO,
morpholino; ATG, translation initiation blocking. Bars in (D) correspond to minimum and maximum values. Boundaries of each box
correspond to 25th and 75th percentiles and horizontal lines within boxes correspond to the median value.myofibrillar mutations observed in this gene,20 that they
may result from de novo mutations or from germ-line
mosaicism in a parent. The remaining mutations were
observed in familial cases. For four mutations (c.211C>T
[p.Arg71Trp], c.367C>T [p.Arg123stop], c.784G>A
[p.Ala262Thr], and c.1430G>A [p.Arg477His]), DNA was
available from additional affected family members, and
all typed positive for these mutations (Figure 1, Table 4).
A single missense variant, p.Val298Met showing very low
conservation scores, was identified in the control popula-
tion alone (Table 3).
The age at onset or diagnosis of the DCM phenotype for
17 subjects harboring one of the eight BAG3 rare variants
(Table 4) ranged from 21 to 64 years (median¼ 44). Disease
severity varied considerably. Although 8 of the 17 muta-
tion carriers with DCM underwent heart transplant or
died with advanced heart failure, a few mutation carriers
had minimal or no disease, including three deletion
carriers in pedigree A, ages 22, 24, and 57 years who
showed lack of pentrance. Such phenotypic variability,
including that related to age-dependent penetrance, has
been widely seen in pedigrees with many different muta-
tions in genes causing DCM.1,2
bag3 Knockdown in a Zebrafish Model
Because a point mutation in BAG3 had been previously
associated with HCM and RCM, we sought to develop
a model of DCM and heart failure. To accomplish this,
we employed a knockdown approach by using morpho-
lino oligonucleotides in the zebrafish. Two different
morpholinos were designed to target zebrafish bag3, one280 The American Journal of Human Genetics 88, 273–282, March 1blocking bag3 translation initiation and one blocking the
splicing donor site at exon 2. The translation initiation-
blocking morpholino specifically introduced heart failure
phenotypes with pericardial effusion and decreased frac-
tional shortening by 14%, p ¼ 0.003, in measurements
from five wild-type fish and six morphants, (Figure 3D),
(see Movies S1 and S2). Peak blood cell flow velocity was
also significantly decreased, p ¼ 0.046, with a mean
maximum velocity of 1287 mM per second in wild-type
fish (n¼ 5) compared to 1045 mMper second inmorphants
(n ¼ 6) (Figure 3E). The second morpholino introduced a
dose-dependent phenotype of both heart failure (Figure 3C
and 3D) and axis curvature (Figure S4) with pericardial
effusion and significantly reduced fractional shortening,
p ¼ 0.0001.Discussion
Collectively, the genetic and pedigree data, showing that
every subject with DCM carried one of the eight BAG3
rare variants, and the zebrafish heart failure data, recapitu-
lating DCM phenotype, provide compelling evidence for
a relevant cause of human adult-onset DCM. Further indi-
cation of BAG3 relevance to DCM is demonstrated by the
observed excess of rare variants in the DCM cohort relative
to our control sample (eight rare variants in cases including
two nonsense and one frameshift compared to three
missense variants in both cases and controls and one
missense in the control population only). Given the often
late onset and phenotypic heterogeneity of DCM, it is1, 2011
possible that some of our control group could go on to
develop DCM or could be asymptomatic carriers of rare
variants. If conservation scores are reliable in disease
prediction, the c.280A>T (p.Ile94Phe) variant could also
be disease causing, as both Phastcon and GERP scores are
high (1 and 5.05, respectively). All other variants observed
in controls show relatively low conservation compared to
variants identified in DCM cases only, suggesting they
are likely polymorphisms of low frequency.
Childhood-onset muscular dystrophy, termed myofi-
brillar myopathy, is dramatically different from the human
DCM; it is caused by a BAG3 point mutation (c.626C>T
[p.Pro209Leu]) accompanied in all cases with RCM or
HCM. Three cases from one Italian and two British fami-
lies19 and four cases in three US families20 showed onset
ranging from 5 to 13 years old, with involvement of skel-
etal, respiratory, and cardiac muscle. Of the seven cases,
three underwent cardiac transplantation (ages 13, 13,
and 14) and two suffered sudden death (ages 9 and
20).19,20 Allelic heterogeneity common to genes disrupted
in DCM has occasionally been associated with muscular
dystrophy,1 most notably with mutations in LMNA (MIM
150330).21 However, the striking phenotypic difference
between the childhood RCM or HCM with myofibrillar
myopathy associated with BAG3 p.Pro209Leu and the
adult-onset DCM observed in association with the eight
BAG3 rare variants in this report suggests fundamental
differences in mechanisms of disease.
BAG3, a member of the Bcl-2-associated athanogene
family, encodes a 535 amino acid protein that has been
classified as a cochaperone of the heat shock proteins
(HSPs). The HSPs function as molecular chaperones, assist-
ing with folding, stabilization, trafficking, and degradation
of cellular proteins, and their disruption can lead to mis-
folded proteins and diseases that stem from abnormal
protein aggregation,22 including expansion-repeat neuro-
degenerative disease proteins.23 Cochaperones such as
BAG3 bind to chaperone proteins, modulating their func-
tion and providing specificity of protein binding or target-
ing to a cellular compartment. Proteins containing the
BAG motif are thought to function primarily in protein
degradation through both the proteasome and autophagy
pathways.22 In addition to the BAG domain that binds to
Bcl-2 and the heat shock proteins Hsp70 and Hsc70,
BAG3 has several other motifs, including Ile-Pro-Val (IPV)
domains that regulate oligomerization.22 The p.Pro209Leu
BAG3 point mutation, modifying the proline in the IPV
domain (Figure 2) and recently shown to interact with
HspB8 and HspB6,23 is thought to provide the specificity
of the childhood-onset phenotype of skeletal and cardiac
myopathy.22,23
Although BAG3 or its binding partners have not yet
been crystallized, extensive prior work with BAG3 biology
suggests that amutant BAG3 protein could disrupt binding
to several key proteins to cause disease. One is Bcl-2, a
protein that protects cells from apoptotic death. The
amount of Bcl-2 has been shown to affect DCM courseThe Ameriand survival in a murine model generated from a mutant
small HSP, HspB5 (CRYAB [MIM 123590], also known as
aB-crystallin).24 aB-crystallin-associated DCM in humans
has also been reported25 and is considered part of the des-
min-related myopathies (DRM [MIM 601419]).24 Both
HspB5 and BAG3 colocalize to the Z disk,18,26 a well estab-
lished DCM gene ontogeny including CSRP3,MYPN (MIM
600824, 608517) and others.1,2 Alternatively, it has been
proposed that BAG3 and Hsc70 interaction is needed to
preserve cardiac myofibrillar integrity under contractile
stress,26 which could also be relevant for the development
of adult-onset DCM. BAG3 has also been shown to modu-
late protein degradation via the proteasomal or autophagic
pathways with aging,27 which might also contribute to the
age of onset and severity of BAG3-mediated DCM.
The observed phenotypic variability in the BAG3 muta-
tion spectrummay also be reflected in our zebrafishmodel.
Translation initiation-blocking of the whole gene gave
a single phenotype of heart failure. In contrast, a second
morpholino that specifically splices out exon 2 resulted
in axis curvature and may be analogous to skeletal myop-
athy (Figure S4).
Our study did not include functional assays to determine
loss or gain of function for specific mutations. The large
deletion observed in pedigree A probably results in a loss
of function or haploinsufficiency, but specific disease
mechanisms for the point mutations are uncertain. In
the case of the nonsense and frameshift mutations,
nonsense-mediated decay could lead to a loss of function,
or alternatively, the presence of a truncated protein could
lead to a gain of function with a more severe phenotype.
Given that DCM is a late onset disease and significantly
less severe than the childhood-onset myofibrillar myop-
athy, one could predict that the DCM mutations are the
result of a loss of function. Further experimental work
will be needed to determine the contribution of these
BAG3 mutations to disease pathology, which may open
a new window to disease treatment.Supplemental Data
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